Logo image of BDR

Blonder Tongue Laboratories Inc (BDR) Stock Fundamental Analysis

NYSEARCA:BDR - NYSE Arca - US0936981085 - Common Stock

0.305  +0 (+1.46%)

After market: 0.305 0 (0%)

Fundamental Rating

1

Overall BDR gets a fundamental rating of 1 out of 10. We evaluated BDR against 49 industry peers in the Communications Equipment industry. BDR may be in some trouble as it scores bad on both profitability and health. BDR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BDR had negative earnings in the past year.
BDR Yearly Net Income VS EBIT VS OCF VS FCFBDR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -2M -4M -6M

1.2 Ratios

Industry RankSector Rank
ROA -5.64%
ROE 2.56%
ROIC -40.64%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDR Yearly ROA, ROE, ROICBDR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -200 -400 -600

1.3 Margins

Industry RankSector Rank
OM -19.82%
PM (TTM) -4.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDR Yearly Profit, Operating, Gross MarginsBDR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 -20 -40

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BDR is destroying value.
BDR has more shares outstanding than it did 1 year ago.
The debt/assets ratio for BDR has been reduced compared to a year ago.
BDR Yearly Shares OutstandingBDR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
BDR Yearly Total Debt VS Total AssetsBDR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M

2.2 Solvency

BDR has an Altman-Z score of -1.77. This is a bad value and indicates that BDR is not financially healthy and even has some risk of bankruptcy.
BDR has a Debt/Equity ratio of 0.64. This is a neutral value indicating BDR is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z -1.77
ROIC/WACC-2.89
WACC14.05%
BDR Yearly LT Debt VS Equity VS FCFBDR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 5M -5M

2.3 Liquidity

BDR has a Current Ratio of 1.11. This is a normal value and indicates that BDR is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 0.38 indicates that BDR may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 0.38
BDR Yearly Current Assets VS Current LiabilitesBDR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 87.82% over the past year.
The Revenue has been growing slightly by 1.67% in the past year.
Measured over the past years, BDR shows a decrease in Revenue. The Revenue has been decreasing by -6.89% on average per year.
EPS 1Y (TTM)87.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.47%
Revenue 1Y (TTM)1.67%
Revenue growth 3Y-10.15%
Revenue growth 5Y-6.89%
Sales Q2Q%2.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDR Yearly Revenue VS EstimatesBDR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BDR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDR Price Earnings VS Forward Price EarningsBDR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.98
BDR Per share dataBDR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BDR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Blonder Tongue Laboratories Inc

NYSEARCA:BDR (6/24/2022, 8:26:09 PM)

After market: 0.305 0 (0%)

0.305

+0 (+1.46%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryCommunications Equipment
Earnings (Last)05-06 2022-05-06
Earnings (Next)N/A N/A
Inst Owners1.05%
Inst Owner Change0%
Ins Owners46.47%
Ins Owner Change0%
Market Cap4.06M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB N/A
EV/EBITDA -1.98
EPS(TTM)-0.07
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.19
BVpS0.18
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.64%
ROE 2.56%
ROCE N/A
ROIC -40.64%
ROICexc N/A
ROICexgc -49.44%
OM -19.82%
PM (TTM) -4.1%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.37
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.11
Quick Ratio 0.38
Altman-Z -1.77
F-Score3
WACC14.05%
ROIC/WACC-2.89
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.47%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.67%
Revenue growth 3Y-10.15%
Revenue growth 5Y-6.89%
Sales Q2Q%2.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A